Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
- Status
- COMPLETED
- Phase
- PHASE3
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects
- Status
- COMPLETED
- Phase
- N/A
Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water
- Status
- COMPLETED
- Phase
- N/A
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
Connectâ„¢ CLL: The Chronic Lymphocytic Leukemia Disease Registry
- Status
- COMPLETED
- Phase
- N/A
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
- Status
- WITHDRAWN
- Phase
- N/A
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease
- Status
- UNKNOWN
- Phase
- PHASE2
B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression
- Status
- COMPLETED
- Phase
- N/A
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging
- Status
- COMPLETED
- Phase
- N/A